Company: DNLI
Filing Date: 2025-12-10
Form Type: 8-K
Source: 0001628280-25-056363
Chunk: 2

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-10
Form: 8-K
Item: Item 8.01
Chunk 2
---
Item 8.01 Other Events.

On December 10, 2025, the Company issued a press release announcing the pricing of the public offering. The press release announcing the pricing of the public offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-Looking Statements

Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company’s expectations regarding the timing and completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering. More information about the risks and uncertainties faced by the Company may be found in the Company’s Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the SEC on February 27, 2025, and November 6, 2025, respectively, and the Company’s subsequent reports filed with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in the Company’s expectations, except as required by law.

Item 9.01 Financial Statements and Exhibits.